IGF-I in the clinics: Use in retinopathy of prematurity

Ann Hellström, David Ley, Ingrid Hansen-Pupp, Boubou Hallberg, Luca A Ramenghi, Chatarina Löfqvist, Lois E H Smith, Anna Lena Hård

Research output: Contribution to journalArticle

Abstract

Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23weeks+0days and 27weeks +6days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
JournalGrowth Hormone and IGF Research
Volume30-31
DOIs
Publication statusPublished - Oct 11 2016

Fingerprint

Retinopathy of Prematurity
Insulin-Like Growth Factor I
Growth
Pathologic Neovascularization
Oxygen
Retinal Vessels
Bronchopulmonary Dysplasia
Insulin-Like Growth Factor Binding Protein 3
Retinal Detachment
Premature Infants
Gestational Age
ROP
Guidelines
Hemorrhage
Pregnancy
Serum

Keywords

  • Review
  • Journal Article

Cite this

Hellström, A., Ley, D., Hansen-Pupp, I., Hallberg, B., Ramenghi, L. A., Löfqvist, C., ... Hård, A. L. (2016). IGF-I in the clinics: Use in retinopathy of prematurity. Growth Hormone and IGF Research, 30-31, 75-80. https://doi.org/10.1016/j.ghir.2016.09.005

IGF-I in the clinics : Use in retinopathy of prematurity. / Hellström, Ann; Ley, David; Hansen-Pupp, Ingrid; Hallberg, Boubou; Ramenghi, Luca A; Löfqvist, Chatarina; Smith, Lois E H; Hård, Anna Lena.

In: Growth Hormone and IGF Research, Vol. 30-31, 11.10.2016, p. 75-80.

Research output: Contribution to journalArticle

Hellström, A, Ley, D, Hansen-Pupp, I, Hallberg, B, Ramenghi, LA, Löfqvist, C, Smith, LEH & Hård, AL 2016, 'IGF-I in the clinics: Use in retinopathy of prematurity', Growth Hormone and IGF Research, vol. 30-31, pp. 75-80. https://doi.org/10.1016/j.ghir.2016.09.005
Hellström A, Ley D, Hansen-Pupp I, Hallberg B, Ramenghi LA, Löfqvist C et al. IGF-I in the clinics: Use in retinopathy of prematurity. Growth Hormone and IGF Research. 2016 Oct 11;30-31:75-80. https://doi.org/10.1016/j.ghir.2016.09.005
Hellström, Ann ; Ley, David ; Hansen-Pupp, Ingrid ; Hallberg, Boubou ; Ramenghi, Luca A ; Löfqvist, Chatarina ; Smith, Lois E H ; Hård, Anna Lena. / IGF-I in the clinics : Use in retinopathy of prematurity. In: Growth Hormone and IGF Research. 2016 ; Vol. 30-31. pp. 75-80.
@article{6e4afa26bc1a4cb5b369131a52447b88,
title = "IGF-I in the clinics: Use in retinopathy of prematurity",
abstract = "Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23weeks+0days and 27weeks +6days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53{\%} reduction in severe bronchopulmonary dysplasia and 44{\%} reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95{\%}, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.",
keywords = "Review, Journal Article",
author = "Ann Hellstr{\"o}m and David Ley and Ingrid Hansen-Pupp and Boubou Hallberg and Ramenghi, {Luca A} and Chatarina L{\"o}fqvist and Smith, {Lois E H} and H{\aa}rd, {Anna Lena}",
note = "Copyright {\circledC} 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2016",
month = "10",
day = "11",
doi = "10.1016/j.ghir.2016.09.005",
language = "English",
volume = "30-31",
pages = "75--80",
journal = "Endocrinology and Metabolism, Supplement",
issn = "1096-6374",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - IGF-I in the clinics

T2 - Use in retinopathy of prematurity

AU - Hellström, Ann

AU - Ley, David

AU - Hansen-Pupp, Ingrid

AU - Hallberg, Boubou

AU - Ramenghi, Luca A

AU - Löfqvist, Chatarina

AU - Smith, Lois E H

AU - Hård, Anna Lena

N1 - Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2016/10/11

Y1 - 2016/10/11

N2 - Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23weeks+0days and 27weeks +6days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.

AB - Retinopathy of prematurity is a potentially blinding disease, which is associated with low neonatal IGF-I serum concentrations and poor growth. In severe cases impaired retinal vessel growth is followed by pathologic neovascularization, which may lead to retinal detachment. IGF-I may promote growth even in catabolic states. Treating preterm infants with recombinant human (rh) IGF-I to concentrations normally found during gestation has been suggested to have a preventative effect on ROP. A recent phase 2 study treating infants (gestational age between 23weeks+0days and 27weeks +6days) with rhIGF-I/IGF binding protein-3 until 30 postmenstrual weeks showed no effect on ROP but a 53% reduction in severe bronchopulmonary dysplasia and 44% reduction in severe intraventricular hemorrhage. Oxygen is a major risk factor for ROP and during the phase 2 study oxygen saturation targets were increased to 90-95%, due to national guidelines, which might have affected ROP rate and severity making increased IGF-I a weaker preventative factor for ROP.

KW - Review

KW - Journal Article

U2 - 10.1016/j.ghir.2016.09.005

DO - 10.1016/j.ghir.2016.09.005

M3 - Article

C2 - 27720550

VL - 30-31

SP - 75

EP - 80

JO - Endocrinology and Metabolism, Supplement

JF - Endocrinology and Metabolism, Supplement

SN - 1096-6374

ER -